Accession Number:

AD1043100

Title:

Development of a PET Prostate-Specific Membrane Antigen Imaging Agent: Preclinical Translation for Future Clinical Application

Descriptive Note:

Technical Report,30 Sep 2015,29 Sep 2016

Corporate Author:

University of California, San Francisco San Francisco United States

Personal Author(s):

• VanBrocklin, Henry

Report Date:

2016-10-01

Pagination or Media Count:

20.0

Abstract:

The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND expIND phase 0 application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen PSMA that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.

Descriptors:

• DIAGNOSTIC TECHNIQUES (MEDICINE)
• Prostate Cancer
• Inhibitors
• proteins
• RADIOCHEMISTRY
• pharmacokinetics
• toxicology
• peptides
• therapeutics
• monitoring
• antigens
• MEMBRANES (BIOLOGY)
• Positron emission tomography

Subject Categories:

• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE